ACM
IRWD icon

Atika Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Atika Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47,760
Closed -$755K – 86
2017
Q2 		$755K Buy
+47,760
New +$694K 0.26% 73

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Atika Capital Management's IRWD Position: Q3 2018 in Review

Atika Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2018, closing a stake of 195,816 shares — an estimated $3.13M sold.

Atika Capital Management first reported a position in IRWD in Q2 2017 and held it in 2 quarters. The position peaked at $3.13M in Q2 2018. 151 funds tracked by Wall St. Rank hold IRWD as of Q3 2018.

  • Atika Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Atika Capital Management sold 195,816 Ironwood Pharmaceuticals shares in Q3 2018, an estimated $3.13M.
  • Atika Capital Management first reported a position in Ironwood Pharmaceuticals in Q2 2017 and held it in 2 quarters.
  • Atika Capital Management's Ironwood Pharmaceuticals position peaked at $3.13M in Q2 2018.
  • 151 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2018.

Based on Atika Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.